论文部分内容阅读
采用随机分组，用肝炎灵肌注治疗慢性迁延性肝炎（ＣＰＨ）及慢性活动性肝炎（ＣＡＨ）各３０例，另用云芝肝泰口服治疗ＣＰＨ及ＣＡＨ各３０例作对照，疗程均为３个月。结果表明，肝炎灵改善患者的临床症状和降低血清丙氨酸转氨酶（ＡＬＴ）的疗效优于对照组。肝炎灵治疗的病例均未发现明显的不良反应
Randomized grouping was used to treat 30 cases of chronic persistent hepatitis (CPH) and chronic active hepatitis (CAH) with hepatitis and intramuscular injection. Another 30 cases of CPH and CAH were treated with Yunzhi Gantai Orally as a control. The duration of treatment was 3 Months. The results showed that Heyanling improved the clinical symptoms of patients and reduced serum alanine aminotransferase (ALT) than the control group. No significant adverse reactions were found in the cases treated with Heyanling